October 13, 2018
Cellular therapies have the potential to make a meaningful difference for patients with neurological disorders, if used correctly.
October 12, 2018
IncobotulinumtoxinA significantly reduced unstimulated salivary flow rate for patients with sialorrhea.
October 12, 2018
Patisiran maintained improvements in mNIS+7 and rapidly halted neurologic disease progression in hATTR amyloidosis.
October 11, 2018
Subcutaneous immunoglobulin is an effective and well-tolerated alternative to intravenous immunoglobulin for myasthenia gravis.
October 11, 2018
Eculizumab showed sustained activity and tolerability through 3 years for generalized myasthenia gravis.